SPRY4-IT1 expression is significantly related to breast cancer resistance to cisplatin, and increased SPRY4-IT1 expression is significantly associated with the lymph node metastasis rate and recurrence; in addition, patients with high spRY4-IT1 expression have lower OS and DFS rates than those with low expression (Zheng et al., 2020). This evidence concerns the gene SPRY4 and breast cancer.